BriaCell prices $4.7 million share offering of 1,449,300 shares at $3.25 each
BriaCell Therapeutics agreed on May 31, 2026 to sell 1,449,300 common shares at $3.25 per share in a best-efforts offering through placement agent ThinkEquity, with the offering closing on June 2, 2026. The Company received gross proceeds of $4.71 million before placement agent fees and expenses, and says it will use the net proceeds for working capital, general corporate purposes and business objectives. The sale adds new shares outstanding, and the placement agent also received warrants, so existing shareholders' ownership may be diluted.
Key points
- 1,449,300 common shares sold at $3.25 per share; gross proceeds of $4.71 million per the 8-K, or about $4.7 million per the press releases
- Placement agent received a cash fee of 7.5% of gross proceeds and warrants to buy 72,465 common shares at $4.0625, exercisable upon issuance and expiring five years from the May 31, 2026 agreement date
- Offering was made under a Form S-3 shelf registration (File No. 333-276650) declared effective January 31, 2024
- The 8-K states the offering closed on June 2, 2025 in one place; the June 2, 2026 closing press release and the filing's signature date indicate 2026
The filing
Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 02, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.